B8FK Stock Overview
A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Biofrontera AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.59 |
| 52 Week High | €11.59 |
| 52 Week Low | €2.03 |
| Beta | 0.41 |
| 11 Month Change | -2.64% |
| 3 Month Change | 8.39% |
| 1 Year Change | -74.41% |
| 33 Year Change | -93.03% |
| 5 Year Change | -97.53% |
| Change since IPO | -99.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| B8FK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.0% | 1.4% | 0.8% |
| 1Y | -74.4% | -18.4% | 9.1% |
Return vs Industry: B8FK underperformed the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: B8FK underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| B8FK volatility | |
|---|---|
| B8FK Average Weekly Movement | 11.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B8FK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: B8FK's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 80 | n/a | www.biofrontera.com |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin.
Biofrontera AG Fundamentals Summary
| B8FK fundamental statistics | |
|---|---|
| Market cap | €16.41m |
| Earnings (TTM) | -€2.57m |
| Revenue (TTM) | €21.67m |
0.8x
P/S Ratio-6.4x
P/E RatioIs B8FK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B8FK income statement (TTM) | |
|---|---|
| Revenue | €21.67m |
| Cost of Revenue | €5.28m |
| Gross Profit | €16.39m |
| Other Expenses | €18.96m |
| Earnings | -€2.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 75.63% |
| Net Profit Margin | -11.85% |
| Debt/Equity Ratio | 0.2% |
How did B8FK perform over the long term?
See historical performance and comparison